Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
LOS ANGELES, May 20, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient’s response to cancer therapy, today announced that abstracts will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL May 31 to June 4, 2013. The abstracts demonstrate the clinical utility of Response Genetics’ proprietary ResponseDX® ERCC1 gene expression test in colon, pancreatic, and lung cancer and the emerging finding that gene mutation and expression profiles in colorectal cancer are associated with tumor location within the colon and rectum.
Help employers find you! Check out all the jobs and post your resume.
